![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright This is an Open Access article: verbatim copying and redistribution of
this article are permitted in all media for any purpose, provided this
notice is preserved along with the article's original DOI Research Uncoupling of ATP-Mediated Calcium Signaling and Dysregulated Interleukin-6 Secretion
in Dendritic Cells by Nanomolar Thimerosal 1 National Institute of Environmental Health Sciences Center for Children’s Environmental Health 2 Department of Veterinary Molecular Biosciences and 3 Department of Medical Pathology, University of California–Davis, Davis, California, USA 4 MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California–Davis, Sacramento, California, USA Address correspondence to I.N. Pessah, Department of Veterinary Medicine, Molecular
Biosciences, 1311 Haring Hall, One Shields Ave., University
of California, Davis, CA 95616 USA. Telephone: (530) 752-6696. Fax: (530) 752-4698. E-mail: inpessah/at/ucdavis.edu The authors declare they have no competing financial interests. Received November 28, 2005; Accepted March 13, 2006. See "Potential Immunotoxic Effect of Thimerosal: Compound Alters Dendritic Cell
Response in Vitro" on page A429a. This article has been cited by other articles in PMC.Abstract Dendritic cells (DCs), a rare cell type widely distributed in the soma, are
potent antigen-presenting cells that initiate primary immune responses. DCs
rely on intracellular redox state and calcium (Ca2+) signals for proper development and function, but the relationship between
these two signaling systems is unclear. Thimerosal (THI) is a mercurial
used to preserve vaccines and consumer products, and is used experimentally
to induce Ca2+ release from microsomal stores. We tested adenosine triphosphate (ATP)-mediated
Ca2+ responses of DCs transiently exposed to nanomolar THI. Transcriptional
and immunocytochemical analyses show that murine myeloid immature DCs (IDCs) and
mature DCs (MDCs) express inositol 1,4,5-trisphosphate receptor (IP3R) and ryanodine receptor (RyR) Ca2+ channels, known targets of THI. IDCs express the RyR1 isoform in a punctate
distribution that is densest near plasma membranes and within dendritic
processes, whereas IP3Rs are more generally distributed. RyR1 positively and negatively regulates
purinergic signaling because ryanodine (Ry) blockade a) recruited 80% more ATP responders, b) shortened ATP-mediated Ca2+ transients > 2-fold, and c) produced a delayed and persistent rise (≥ 2-fold) in baseline
Ca2+. THI (100 nM, 5 min) recruited more ATP responders, shortened the ATP-mediated
Ca2+ transient (≥ 1.4-fold), and produced a delayed rise (≥ 3-fold) in
the Ca2+ baseline, mimicking Ry. THI and Ry, in combination, produced additive
effects leading to uncoupling of IP3R and RyR1 signals. THI altered ATP-mediated interleukin-6 secretion, initially
enhancing the rate of cytokine secretion but suppressing cytokine
secretion overall in DCs. DCs are exquisitely sensitive to THI, with
one mechanism involving the uncoupling of positive and negative regulation
of Ca2+ signals contributed by RyR1. Keywords: calcium, calcium channel, dendritic cell, ethyl mercury, immunotoxicity, interleukin-6, organic mercury, redox, thimerosal Recent animal and human studies have underscored the strong influence of
genetic, epigenetic, and physiologic factors in defining susceptibility
of the immune system to methylmercury (MeHg) and ethylmercury (EtHg) (Havarinasab and Hultman 2005; Lawler et al. 2004; Silbergeld et al. 2005). Immune dysregulation triggered by organic mercury can include suppression, stimulation, loss
of tolerance, and generation of auto-antibodies. Therefore, the
pattern of immunotoxicity induced by organic mercury
is likely to depend not only on the chemical form, timing, and dose
to which an individual is exposed but also on susceptibility factors that
are poorly understood at present. Thus, significant attention is currently
focused on identifying which types of immune cells and biomolecules
are critical targets of low-level organic mercury and their functional
consequences on overall immune status. Sodium ethylmercurithiosalicylate (thimerosal; THI) is an EtHg-containing
compound used to preserve cosmetics, blood products, and vaccines and
is also used experimentally to induce calcium (Ca2+) release from microsomal [endoplasmic reticulum/sarcoplasmic reticulum (ER/SR)] stores in intact cells. THI toxicity is due
to the EtHg moiety. THI and EtHg toxicity in humans consist of a few cases
of accidental high-dose poisoning (Cinca et al. 1980; Damluji 1962; Zhang 1984). Attention has been focused on THI in vaccines, where it is used as a
preservative for multiuse formulations. THI was withdrawn from pediatric
vaccines starting in 1999 (Centers for Disease Control and Prevention 1999) over concerns that organic mercury is a known neurodevelopmental toxicant. Nevertheless, THI
is still used in influenza, diphtheria toxoid, diphtheria
toxoid and acellular pertussis (DTaP), and tetanus toxoid
vaccines. The hypothesis that THI can cause neurodevelopmental disorders
was tested by injecting THI and THI-containing vaccines into inbred
strains of young mice (Hornig et al. 2004). Growth, behavioral, and histologic abnormalities in the brains of the
autoimmune susceptible strain (SJL) were recorded after administration
of THI or THI plus vaccine. Autoimmune-resistant strains (C57BL/6, BALB/c) did
not display any of the abnormalities, suggesting a strong
influence of inherent immune status and the neurodevelopmental toxicity
of THI. We hypothesized that especially sensitive targets of THI-mediated immune
dysregulation are dendritic cells (DCs), whose function is to acquire
antigens derived from self or nonself sources and efficiently present
them to naive and resting T cells (Banchereau and Steinman 1998). This hypothesis stems from the fact that ambient oxygen (O2) tension or thiol concentration directly influences DC secretion of interferon-γ (IFN-γ) and interleukin-12 (IL-12) (Murata et al. 2002), enhances expression of Fc R1, the high affinity receptor for
IgE (Novak et al. 2002), and regulates surface class II major histo-compatibility complex (MHC) expression (Goth et al. 2006) in vitro. In this regard, Ca2+ contributes essential signals for DC function and maturation. Differentiation (Bagley et al. 2004), pro-inflammatory cytokine secretion (Gardella et al. 2000), apoptotic cell phagocytosis (Poggi et al. 1998), and migrational responsiveness to purine nucleotides or chemokines (Partida-Sanchez et al. 2004; Scandella et al. 2004) are Ca2 +-dependent processes. DCs rely on changes in intracellular redox state
and Ca2+ signals for proper development and function, but the relationship between
these signaling systems in DCs is unclear.THI contains an oxidized mercury atom (Hg2+) whose redox properties can enhance the activity of the inositol 1,4,5-trisphosphate
receptor (IP3R) and ryanodine receptor (RyRs), both intracellular Ca2+ channels (Kaplin et al. 1994; Pessah et al. 2002). THI elicits Ca2+ release from ER/SR stores in lymphocytes (Bultynck et al. 2004) and ER/SR microsomes by targeting the IP3R and RyR (Abramson et al. 1995; Kaplin et al. 1994). THI-treated, monocyte-derived DCs failed to or only minimally phosphorylated
STAT (signal transducer and activator of transcription) proteins 1, 3, 4, and 6, implying that the JAK (janus kinase) signaling pathway
and, by extension, cytokine receptors are bypassed in the sensitization
phase induced by THI (Valk et al. 2002). DCs express several classes of Ca2+ channel proteins that mediate Ca2+ signals. DCs express store-operated Ca2+ channels (Hsu et al. 2001) and IP3Rs that regulate release of Ca2+ from ER/SR stores in response to adenosine triphosphate (ATP) (Schnurr et al. 2003) and chemokines (Scandella et al. 2004). Immature DCs (IDCs) express message for one of three genetic forms of
the RyR, the RyR1 (Hsu et al. 2001; O’Connell et al. 2002). The influence of THI and its metabolites EtHg and thiosalicylic acid (TSA) on
Ca2+ signaling and activation of DCs remain unexplored. To study how THI and EtHg influence Ca2+-dependent DC functions, we generated and tested murine DCs under normoxia (5% O2 vol/vol) and omitted 2-mercaptoethanol (2-Me) from the culture medium. In
this article we report that DCs primarily express the type 1 isoform
of the IP3R and RyR ER/SR Ca2+ channels, known targets of THI. THI and ryanodine (Ry) each block early
positive contributions of the RyR1 to ATP-induced Ca2+ transients and uncouple inhibitory feedback, indicating a common mechanism. The
consequences of THI upon ATP-induced IL-6 production, a Ca2+-dependent process, were examined. THI initially enhanced the IL-6 secretion
rate, but ultimately suppressed its accumulation. DCs are exquisitely
sensitive to THI, with one prominent mechanism involving the uncoupling
of positive and negative regulation of Ca2+ signals contributed by RyR1. Materials and Methods Chemicals and antibodies THI (USP grade) and its metabolite TSA, propidium iodide (PI), diethylpyrocarbonate, and
Na2ATP were purchased from Sigma (St. Louis, MO). We purchased fibronectin (bovine
plasma) from Calbiochem (San Diego, CA) and ethyl-mercuric chloride (EtHgCl) from
ICN (Costa Mesa, CA). Recombinant murine granulocyte/macrophage
colony stimulating factor (GM-CSF) was purchased from Sigma
or R&D Systems (Minneapolis, MN), as were murine IL-6 ELISA kits. Antibodies (BD-Pharmingen, San Diego, CA) are as follows (clone name): class
II MHC-biotin (2G9), CD11c-APC (HL3), CD16/32 (2.4G2), and
hamster immunoglobulin. Anti-RyR monoclonal antibody 34C (recognizes
types 1 and 3) was purchased from the Developmental Studies Hybridoma
Bank (Iowa City, IA). Anti-IP3R and anti-IP3R1 polyclonal antibodies were purchased from Chemicon (Temecula, CA). Prolong
Antifade, Fura-2 AM, Fluo-4 AM, Alexa 488–conjugated goat
anti-mouse IgG antibody, Alexa 488–conjugated goat anti-rabbit
IgG antibody, and Alexa 647–conjugated goat anti-rabbit IgG
antibody were purchased from Invitrogen (Carlsbad, CA). 7-Aminoactinomycin
D (7AAD) was purchased from Calbiochem. A fluorescent terminal
deoxynucleotidyl transferase (TdT) labeling kit was purchased from Promega (Madison, WI). Cell culture Female C57BL/6J mice 6–8 weeks of age were purchased from JAX West, Inc. (Davis, CA), treated humanely and with regard for alleviation
of suffering, and euthanized in accordance with a protocol approved
by the University of California–Davis Animal Resources Service. Bone-marrow–derived DCs were generated by modifying a protocol (Lutz et al. 1999), using normoxia (5% O2 vol/vol), and omitting 50 μM 2-Me from the culture medium (Goth et al. 2006). R10 medium was RPMI 1640 (Invitrogen) with 10% fetal bovine
serum (FBS; Hyclone, Logan, UT), 2 mM l-glutamine, 2 mM sodium pyruvate, 100 IU/mL penicillin, and 10 μg/mL
streptomycin. Cultures were maintained at 37°C in a Thermo
Forma model 3130 incubator (Thermo Forma, Marietta, OH) equipped with
a CO2 and fuel-cell O2 monitor and N2 and CO2 gas supplies. CO2 was set to 5% vol/vol, and O2 to 5% vol/vol, and were periodically verified using Fyrite gas
analyzers (Bacharach Inc., New Kensington, PA). DC cytometric flow sorting and analysis Cells were flow sorted between culture days 6 and 10. A detailed description
of our cell preparation for flow cytometry has been published (Goth et al. 2006). Briefly, nonadherent cells were preblocked with 2.4G2 monoclonal antibody (1.0 μg/mL) and hamster IgG (0.25 μg/mL) for 10 min. Fluorescent
anti-class II MHC (0.1 μg/mL) and anti-CD11c (0.3 μg/mL) monoclonal antibodies were added and allowed to bind
for 15 min. After washing with 2% FBS in phosphate-buffered
saline (PBS), cells were aseptically sorted on a MoFlo cytometer (Cytometric, Fort
Collins, CO). Single-stained and unstained controls were
used to define sorting gates and to adjust compensation. CD11c-positive
cells were considered DCs and graded as IDCs or mature DCs (MDCs) depending
on their class II MHC expression. We routinely obtained ≥ 85% purities
of sorted IDC and MDC subsets. PI was added
to a final concentration of 0.5 μg/mL before sorting or before
analysis on a FACScan flow cytometric analyzer (Becton Dickinson, Palo
Alto, CA) to detect dead cells. DC treatment THI, EtHgCl, and TSA solutions were dissolved in sodium carbonate using
borosilicate glass pipettes and tubes. Dilutions were made in R10 and
used within 1 hr. DCs (1–2 × 106 cells/mL) were aliquoted into perfluorocarbon tissue culture vials or 96-well
format plates (Savillex, Minnetonka, MN). R10 or medium containing
THI, EtHgCl, TSA, or lipopolysaccharide (LPS) (to 1 μg/mL) was
added, and cells were placed in a 37°C incubator. DC transcriptome analysis Total RNA was isolated from sorted DCs using Trizol Reagent (Molecular
Research Center, Cincinnati, OH) according to the manufacturer’s
recommended procedure. DCs were resuspended to 1 × 106 cell/mL
in R10 media, plated in per-fluorocarbon containers, and incubated
for 20 hr. Biotinylated cRNA was synthesized from 5 μg of total
cellular RNA according to the protocol published by Affymetrix Inc. (Affymetrix 2004). Fragmented, labeled cRNA was hybridized onto Affymetrix mouse 430A or 430 2.0 GeneChip
arrays. Microarrays were hybridized 16 hr at 45°C, stained, and
washed according to an Affymetrix protocol (EukGE-WS2v4; Affymetrix 2004). Fluorescence intensity was measured with a scanner equipped with Affymetrix
Microarray Analysis Suite version 5.0. The average intensity for
each array was normalized by scaling to a target intensity value of 125, allowing
comparison between arrays. Individual transcripts are represented
by perfect-match probes in conjunction with a corresponding
set of mismatch probes. A transcript is called present if the average
intensity value of perfect-match cells is ≥ 1.5 times greater
than the average intensity of mismatch cells, and the average intensity
difference between perfect-match and mismatch cells is four or more
times the experimental noise. Poorly performing probes (where the ratio
between the average intensity of mismatch cells and perfect-match cells
is four or more times the experimental noise) were not included in
the analysis. RNA from three independent cultures was analyzed on GeneChips (i.e., three
GeneChips per treatment were analyzed). Immunocytofluorescence of calcium channels DCs were washed in 1% bovine serum albumin (BSA) in PBS, centrifuged
onto glass slides using a Cytofuge2 (Statspin, Norwood, MA), air
dried, fixed with 4% paraformaldehyde in PBS for 20 min at 4°C, and
then permeabilized with three washes of 0.2% Tween-20 in
PBS (TPBS). Nonspecific binding was blocked with goat IgG (50 μg/mL). Cells
were incubated with primary antibody (dilutions
were 1:20 34C and 1:100 anti-IP3R and IP3R1 polyclonal antibodies in TPBS) for 1 hr. Blocking peptide for the IP3R1 antibody was used at the manufacturer’s suggested concentration. After
washing, Alexa 488– or Alexa 647–conjugated
anti-mouse and anti-rabbit secondary antibodies were diluted 1:1,000 in
TPBS and allowed to bind 1 hr. Cells were washed with TPBS and then
with PBS. After mounting with Prolong Antifade plus 40 μg/mL 7AAD, DCs
were visualized for immunofluorescence using an MRC 600 laser
scanning confocal microscope (Bio-Rad, Richmond, CA). Confocal immunopheno-typing
was performed on two separate cultures. TdT assay IDCs were treated with 500 nM TSA, THI, or medium for 20 hr as described
above. Cells were then washed twice with ice-cold PBS and fixed with 4% paraformaldehyde in PBS for 20 min on ice. Cells were washed
in 1% BSA in PBS and resuspended to 0.5 × 106 cells/mL
in 1% BSA in PBS; cell aliquots were then spun onto microscope
slides. Slides were air dried at least 2 hr and then immersed in 4% diethylpyrocarbonate:ethanol prechilled to –20°C
for 30 min to stop endogenous nuclease activity. After washing twice
with PBS, cells were processed for DNA strand end-labeling according
to the protocol supplied by the kit manufacturer (Promega). After
TdT labeling, nuclei were counterstained with 1 μg/mL PI in water
for 15 min before mounting in Prolong Antifade for confocal imaging. [3H]Ryanodine binding analysis High-affinity binding of [3H]ryanodine ([3H]Ry; 56 or 50 Ci/mmol; PerkinElmer, Boston, MA) to rabbit skeletal
microsomes enriched in RyR1 was performed as previously described (Pessah et al. 1987). Nonspecific binding was determined by including 1,000-fold unlabeled
Ry. Data were reported in picomoles of bound Ry per milligram of protein. IL-6 assays IDCs were pulsed with 100 nM THI or TSA for 20 min, pelleted, supernatant
aspirated, and resuspended to 2 × 107/mL; 0.05 mL of the cell suspension was aliquoted per well into a perfluorocarbon 96-well
plate, and 0.05 mL ATP (0, 0.2, 2, or 20 μM
final) was added per well. Medium and LPS (1 μg/mL final) cells
received no pre-treatment. Supernatants for IL-6 ELISA were collected 20 hr
later from the top portion of the cultures. IL-6 concentrations
were interpolated from the linear response range of the cytokine standard; minimum
sensitivity was 7 pg/mL. Calcium imaging IDCs were resuspended in R10 supplemented with 5 ng/mL recombinant murine
GM-CSF to 0.5 × 106/mL; 0.5 mL was plated overnight onto fibronectin-coated glass coverslips. The
next day, cells were labeled with 5 μM Fura-2 AM or Fluo-4 AM
for 20 min. Cells were washed with bathing solution (130 mM NaCl, 4 mM
KCl, 10 mM HEPES, 10 mM glucose, 2 mM CaCl2, 2 mM MgSO4, pH 7.3, with NaOH) and imaged within 1 hr. Changes in cytoplasmic Ca2+ were measured by emission at 510 nm (Fluo-4) or ratioing emission at 510 nm
with excitation pair 340/380 nm (Fura-2) (Fessenden et al. 2003). Rapid perfusion of ATP and caffeine was accomplished by a micropipette
above the cells being imaged (Automate, Oakland, CA). Data analysis Nonlinear curve fitting analysis and one-way analysis of variance were
performed using Origin 6.0 (OriginLab Corporation, Northampton, MA) software
to test for statistical significance. Results Culturing murine bone marrow at physiologic O2 tension (5% vol/vol) without 2-Me supplementation generated myeloid
IDCs and MDCs with a similar yield, leukocyte marker expression, and
allostimulatory capacity as DCs produced from cultures using ambient (20%) O2 and 50 μM 2-Me (Goth et al. 2006). A representative flow cytometric dot plot showing sorting gates for
IDCs and MDCs is shown in Supplemental Material, Figure 1A
IDCs express IP3R1 in a dense granular distribution in a pattern consistent with targeting
to ER membranes (Figure 1A,E Ca2+ responses of IDCs to the RyR agonist caffeine were tested. Given the expression
of RyR1 within IDCs, and that MDCs respond to caffeine (Schnurr et al. 2003), we expected IDCs would respond to caffeine with a rise in cytoplasmic
Ca2+. Approximately 50% of IDCs responded to 20 mM caffeine (Figure 2A
Range-finding experiments determined that a 20 hr exposure to 10 μM
THI consistently killed > 90% of DCs using flow cytometry, judged
by their increased permeability to PI and decreased cell size [forward
light scatter (FSC); data not shown]. THI, EtHgCl, and
TSA were titrated from 50 nM to 10 μM, IDC and MDC
subsets were treated for 20 hr, and cell PI permeability was measured
by flow cytometry. Figure 3A and B
Lymphocyte tolerance or immunity to an antigen can be driven by IDCs or
MDCs, respectively (Steinman et al. 2005), and we focused on characterizing the effects of THI upon ATP-mediated
Ca2+ signaling (a maturation signal) in IDCs. THI can release Ca2+ from ER/SR stores by selectively enhancing the activity of IP3R and RyR, and we examined its actions on ATP-mediated Ca2+ signaling in IDC. ATP is an efficacious activator of DCs through its agonist
actions on P2Y purinergic nucleotide receptors (Idzko et al. 2002). P2Y receptors couple to Gαq protein that initiates signal transduction
events leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to IP3 and diacylglycerol. IP3 in turn activates IP3R that mobilizes Ca2+ from ER stores (Di Virgilio et al. 2001a, 2001b). IDCs challenged with two pulses of 20 μM ATP (5 sec each) 30 min
apart (with constant perfusion) produced Ca2+ transients whose peak heights, baseline to peak rates, or peak to baseline
decays were not significantly different (Figure 4A
Perfusion of 50 nM THI after an initial ATP test pulse (Figure 4B ATP generated a stereotyped Ca2+ transient having a time to peak of 16.1 ± 2.6 sec and a decay
time of 106 ± 2.6 sec (Figure 5A
The effects of THI and Ry in combination were nearly additive (Figure 5A Increased intracellular Ca2+ induced by inhibitors of the ER/SR Ca2+-ATPase is associated with the rapid secretion of macrophage IL-6 (Bost and Mason 1995). DCs produce IL-6 in response to IL-1β, tumor necrosis factor-α, or
LPS, and other myeloid cells secrete IL-6 in response to ATP (Shigemoto-Mogami et al. 2001). We hypothesized that THI-induced uncoupling of ATP-mediated Ca2+ signaling would disrupt IL-6 secretion. IDCs were pretreated with 100 nM
THI or TSA and challenged with graded concentrations of ATP, and secreted
IL-6 was measured. Figure 6A
Figure 6B Discussion DC activation and associated immune functions are subject to regulation
by their redox environment (Bagley et al. 2004; Gardella et al. 2000; Goth et al. 2006; Murata et al. 2002; Novak et al. 2002). We generated DCs under tightly regulated O2 and without 2-Me to provide a more physiologic baseline to study the mechanism
of redox active environmental triggers such as THI and EtHg in
regulating DC activation in vitro. For DCs, Ca2+ signaling events provide an essential “upstream” component, engaging
immediate events such as cytokine production and secretion (Ferrari et al. 2000; la Sala et al. 2002) and long-term (e.g., maturational) responses. Importantly, microsomal
IP3R and RyR Ca2+ channel functions are tightly regulated by changes in local redox state (Bultynck et al. 2004; Kaplin et al. 1994; Pessah et al. 2002). We show for the first time the expression and distribution of two major
Ca2+ channel proteins expressed in DCs. We have provided transcriptomal and
direct immunocytochemical evidence that DCs express specific isoforms
of the IP3R and RyR Ca2+ channels. RyR and IP3R proteins distinctly distribute in DC subsets. In IDCs, RyR1 and IP3R1 localize below the plasma membrane at the base of the dendrites and
into the processes. A similar distribution of the RyR was seen in MDCs. However
IP3Rs extend to reticular regions where the RyR1 is either absent or at very
low levels. In human monocytes, IP3R and RyR localization patterns similar to our murine DCs were found (Clark and Petty 2005). ATP-triggered Ca2+ transients in IDCs have three components that engage cross-talk between
IP3Rs and RyRs. The initial rate and amplitude of the Ca2+ transient (phase 1; Figure 7
However, RyR1 activity in IDCs also contributes to the negative regulation, reestablishing
a stable resting Ca2+ level near that before activation of purinergic signaling (phase 3; Figure 7 Collectively, these data show that RyR1 channels are closely coupled to
IP3-induced Ca2+ release and contribute to the temporal properties of the transient by
prolonging the decay and restoring the original resting Ca2+ level. RyR1 therefore contributes both positive and negative regulation
to purinergic signaling in IDCs. THI, like Ry, appears to uncouple RyR1 functions
from phosphoinositide signaling in IDCs in a concentration- and
time-dependent manner. Nanomolar THI deregulated ATP-mediated signaling by a mechanism that uncoupled
phases 2 and 3 of the Ca2+ transient. THI did not appear to influence the initial response to ATP
by activation of the IP3R (phase 1) but enhanced the transient decay rate after agonist withdrawal (phase 2) and
elicited a persistent rise in intracellular Ca2+ (phase 3). THI’s actions on IP3R-mediated signals have not been previously explored in DCs. However, evidence
indicates that IP3R1 is a target of THI. Using triple-IP3R-knockout R23-11 cells derived from DT40 chicken B lymphoma cells, THI (1–100 nM) potentiated IP3-induced Ca2+ release when IP3R1, but not IP3R3, is expressed (Bultynck et al. 2004). RyR1 is also a sensitive target of THI (Figure 3E DC sensitivity to their oxidative environment may reflect how they generate
and use Ca2+ signals in response to a changing redox environment. Redox modulation
of DC function is underscored by our finding that THI modulates IL-6 synthesis
elicited by exogenous ATP. Myeloid DC IL-6 strongly influences
mucosal T-cell and gut B-cell responses. Lung DCs with intrinsic TH2-polarizing activities generated TH1 responses from naive CD4+ T cells in the presence of anti–IL-6 neutralizing
antibody (Dodge et al. 2003). Peyer’s patch B cells were induced to secrete IgA by IL-6 elaborated
by local CD11b-positive DCs; IgA induction was reduced by anti–IL-6 antibodies (Sato et al. 2003). In vivo ATP steady-state levels are at nanomolar and low micromolar (1–25 μM) concentrations in bulk fluids and at the cell surface, respectively (Lazarowski et al. 2003). At these concentrations, metabotropic G-protein–coupled P2Y
receptors are engaged. In THI-treated DCs, IL-6 production kinetics are
enhanced by 2 μM and 20 μM ATP, and IL-6 secretion is
significantly suppressed by 0.2 μM ATP (Figure 6A A practical implication of the present findings has relevance to the commercial
uses of THI as an antimicrobial agent in vaccines and consumer
products because they identify DCs as sensitive targets for THI- and
EtHg-mediated dysfunction. Given the importance of DCs as a front line
in regulating lymphocyte-mediated immunity and tolerance, altering DC
functions by forms of EtHg should be considered when assessing contributions
to altered immune function. In studies using the autoimmune-susceptible
A.SW (H-2s) mouse strain, THI induces a syndrome that is stronger and more generally
manifested than those produced by methylmercury (Havarinasab et al. 2004), and development of autoimmunity in H-2s mice is dependent on cellular (T cell) and soluble (IFN-γ and
IL-6) factors (Havarinasab et al. 2005). Onset of spontaneous systemic autoimmune disease symptoms (proteinuria, anti-DNA
antibodies) in (NZBxNZW)F1 mice is hastened by THI (Havarinasab and Hultman 2006). Interestingly, disease morbidity and mortality in these F1 mice are dramatically reduced by neutralizing anti–IL-6 receptor
antibody (Mihara et al. 1998), an effect associated with reduced IgG (auto-) antibody production. The human RyR1 gene is highly polymorphic. More than 60 single missense or deletional
mutations have been closely linked to the pharmacogenetic disorders malignant
hyperthermia and central core disease (Gronert et al. 2004). Our findings that DCs primarily express the RyR1 channel complex and
that this complex is uncoupled by very low levels of THI with dysregulated
IL-6 secretion raise intriguing questions about a molecular basis
for immune dyregulation and the possible role of the RyR1 complex in
genetic susceptibility of the immune system to mercury. Footnotes Supplemental Material is available on online at http://www.ehponline.org/docs/2006/8881/suppl.pdf We thank C. Kwong for cytokine analyses and J. van de Water (Department
of Medicine, Division of Rheumatology, Allergy and Clinical Medicine, University
of California–Davis) for helpful discussions and for
reviewing the manuscript. This work was supported by the National Institute of Environmental Health
Sciences (NIEHS) Center for Children’s Environmental Health (grant
PO1 ES11269), the U.S. Environmental Protection Agency through
the Science to Achieve Results (STAR) program (grant R829388), and the
MIND Institute. Additional support came from the NIEHS Center for Environmental
Health Sciences Cellular Imaging Core (grant ES05707). This
investigation was conducted in a facility contructed with support from
Research Facilities Improvement Program grant C06 RR-12088-01 from
the National Center for Research Resources, National Institutes of Health. Supplemental Figures and Tables Click here to view.(136K, pdf) References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Autoimmun Rev. 2005 Jun; 4(5):270-5.
[Autoimmun Rev. 2005]Ment Retard Dev Disabil Res Rev. 2004; 10(4):292-302.
[Ment Retard Dev Disabil Res Rev. 2004]MMWR Morb Mortal Wkly Rep. 1999 Jul 9; 48(26):563-5.
[MMWR Morb Mortal Wkly Rep. 1999]Mol Psychiatry. 2004 Sep; 9(9):833-45.
[Mol Psychiatry. 2004]Nature. 1998 Mar 19; 392(6673):245-52.
[Nature. 1998]Eur J Immunol. 2002 Oct; 32(10):2866-73.
[Eur J Immunol. 2002]J Invest Dermatol. 2002 Oct; 119(4):842-9.
[J Invest Dermatol. 2002]J Immunol Methods. 2006 Jan 20; 308(1-2):179-91.
[J Immunol Methods. 2006]Clin Diagn Lab Immunol. 2004 Jan; 11(1):77-82.
[Clin Diagn Lab Immunol. 2004]J Biol Chem. 1994 Nov 18; 269(46):28972-8.
[J Biol Chem. 1994]Front Biosci. 2002 May 1; 7():a72-9.
[Front Biosci. 2002]Biochem J. 2004 Jul 1; 381(Pt 1):87-96.
[Biochem J. 2004]J Biol Chem. 1995 Dec 15; 270(50):29644-7.
[J Biol Chem. 1995]Arch Dermatol Res. 2002 Jul; 294(4):163-7.
[Arch Dermatol Res. 2002]J Immunol Methods. 1999 Feb 1; 223(1):77-92.
[J Immunol Methods. 1999]J Immunol Methods. 2006 Jan 20; 308(1-2):179-91.
[J Immunol Methods. 2006]J Immunol Methods. 2006 Jan 20; 308(1-2):179-91.
[J Immunol Methods. 2006]Mol Pharmacol. 1987 Mar; 31(3):232-8.
[Mol Pharmacol. 1987]J Biol Chem. 2003 Aug 1; 278(31):28727-35.
[J Biol Chem. 2003]J Immunol Methods. 2006 Jan 20; 308(1-2):179-91.
[J Immunol Methods. 2006]Blood. 2003 Jul 15; 102(2):613-20.
[Blood. 2003]J Immunol. 2001 Feb 1; 166(3):1611-7.
[J Immunol. 2001]Blood. 2002 Mar 1; 99(5):1715-22.
[Blood. 2002]J Immunol. 2000 Oct 15; 165(8):4704-9.
[J Immunol. 2000]Clin Diagn Lab Immunol. 2004 Jan; 11(1):77-82.
[Clin Diagn Lab Immunol. 2004]Adv Exp Med Biol. 2005; 560():83-97.
[Adv Exp Med Biol. 2005]Blood. 2002 Aug 1; 100(3):925-32.
[Blood. 2002]Trends Pharmacol Sci. 2001 Jan; 22(1):5-7.
[Trends Pharmacol Sci. 2001]Blood. 2001 Feb 1; 97(3):587-600.
[Blood. 2001]J Biol Chem. 1992 Nov 25; 267(33):23560-7.
[J Biol Chem. 1992]Mol Pharmacol. 1992 Dec; 42(6):1049-57.
[Mol Pharmacol. 1992]J Immunol. 1995 Jul 1; 155(1):285-96.
[J Immunol. 1995]J Neurochem. 2001 Sep; 78(6):1339-49.
[J Neurochem. 2001]Clin Diagn Lab Immunol. 2004 Jan; 11(1):77-82.
[Clin Diagn Lab Immunol. 2004]FEBS Lett. 2000 Sep 22; 481(3):245-8.
[FEBS Lett. 2000]J Immunol Methods. 2006 Jan 20; 308(1-2):179-91.
[J Immunol Methods. 2006]Eur J Immunol. 2002 Oct; 32(10):2866-73.
[Eur J Immunol. 2002]J Invest Dermatol. 2002 Oct; 119(4):842-9.
[J Invest Dermatol. 2002]J Histochem Cytochem. 2005 Jul; 53(7):913-6.
[J Histochem Cytochem. 2005]Biochem J. 2004 Jul 1; 381(Pt 1):87-96.
[Biochem J. 2004]J Biol Chem. 1995 Dec 15; 270(50):29644-7.
[J Biol Chem. 1995]Biophys J. 2000 Jul; 79(1):279-86.
[Biophys J. 2000]Biophys J. 2003 Apr; 84(4):2319-30.
[Biophys J. 2003]J Biol Chem. 1994 Dec 30; 269(52):33028-34.
[J Biol Chem. 1994]J Biol Chem. 2004 Aug 13; 279(33):34514-20.
[J Biol Chem. 2004]J Immunol. 2003 May 1; 170(9):4457-64.
[J Immunol. 2003]J Immunol. 2003 Oct 1; 171(7):3684-90.
[J Immunol. 2003]Mol Pharmacol. 2003 Oct; 64(4):785-95.
[Mol Pharmacol. 2003]J Immunol. 1995 Jul 1; 155(1):285-96.
[J Immunol. 1995]J Biol Chem. 1995 Dec 15; 270(50):29644-7.
[J Biol Chem. 1995]Toxicol Appl Pharmacol. 2004 Jan 15; 194(2):169-79.
[Toxicol Appl Pharmacol. 2004]Toxicol Appl Pharmacol. 2005 Apr 15; 204(2):109-21.
[Toxicol Appl Pharmacol. 2005]Clin Exp Immunol. 1998 Jun; 112(3):397-402.
[Clin Exp Immunol. 1998]